Fruquintinib in the Cross-line Treatment of Refractory mCRC
收藏NIAID Data Ecosystem2026-05-01 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/114606
下载链接
链接失效反馈官方服务：
资源简介：
This is a real-world study. Patients with metastatic colorectal cancer who have progressed (PD) after third-line treatment with fruquintinib combined with PD-1 inhibitors will receive fruquintinib combined with TAS-102 as fourth-line therapy. The objective of this study was to observe the efficacy and safety of cross-line（from third to fourth line）treatment with fruquinitinib.
创建时间：
2023-10-15
